Background. Retrorectal sarcomas are rare, and limited data are available on oncologic outcomes following surgery. Our aim was to evaluate outcomes in this patient population at our institution. Materials and Methods. All patients who underwent surgical resection of a malignant retrorectal/presacral sarcoma between 1985 and 2005 were identified. Data analyzed included demographics, histopathologic diagnosis, surgical morbidity and mortality, use of adjuvant therapy, local and distant recurrence, and survival. Results. A total of 37 patients were identified (20 males) with a median age of 49 years (range, 22-81 years). The most common histopathologic diagnosis was malignant peripheral nerve sheath tumor (n = 8). Also, 22 tumors were high grade and 15 were low grade. Surgical margin status was R0 in 31 patients and R1 in 6. Adjuvant therapy was given to 26 patients. Postoperative morbidity and mortality was 57% and 3%, respectively. Median length of follow-up in 16 patients alive at last contact was 4.7 years. The 5-year survival free of local (LDFS), distant (DDFS), and local or distant recurrence (DFS) was 51, 58, and 39%, respectively. Patient survival at 2, 5, and 10 years was 75, 55, and 47%, respectively. Disease-free survival was not significantly associated with gender (P = .16), primary vs secondary (P = .94), R0 vs R1 resection (P = .26), low vs high tumor grade (P = .17), or the use of surgery with or without adjuvant therapy (P = .33). Conclusions. Retrorectal sarcomas are often high grade and locally advanced. Most tumors are resectable with free margins, and long-term survival may be possible in up to one-half of patients following an aggressive surgical approach.
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Patients with malignant tumors arising in the retrorectal or presacral space present a significant challenge to pelvic surgeons. Diverse pathology, delayed presentation, and locally advanced disease characterize these lesions. An aggressive surgical approach may not always be considered because of the lack of technical expertise, and the surgeon's concern that operative complications and postoperative disability will be too high.
Of the wide range of malignant tumors arising in the retrorectal space, sacrococcygeal chordomas are the most common.
1-3 Surgical management and oncologic outcomes of these tumors have been well described with 5-year disease-free survival reported to be as high as 60%. 4 On the contrary, surgical management of nonchordoma malignant retrorectal tumors has only been reported in small series or single-case reports, and therefore limited data exist on long-term oncologic outcomes. 1, 3 In a previous analysis of malignant retrorectal tumors by our institution, we found that the majority of nonchordoma retrorectal tumors were sarcomas.
3 In that series, oncologic outcomes were poor, but this was early in our experience and prior to the routine use of a multidisciplinary approach.
Because of the location of some pelvic sarcomas in the retrorectal space, colorectal surgeons may be asked to evaluate and make treatment recommendations for these patients. Given the advances in surgical technique and adjuvant therapy over the last 20 years, we aimed to evaluate our results in patients with retrorectal sarcomas in the modern era that included a multidisciplinary management approach.
METHODS
Following approval by the Institutional Review Board, the prospectively maintained Surgical Pathology and Tumor Registry databases at the Mayo Clinic Rochester (MCR) were examined to identify all patients who underwent surgery for a retrorectal tumor between 1985 and 2005. Operative notes and imaging studies were reviewed to confirm that all lesions extended into, or were primarily located in, the retrorectal or presacral space. Primary sacral-based tumors that extended into and occupied the retrorectal space were included. The anatomical definition of what constitutes this space has been published previously.
5 Sarcomas confined to the sacrum, nonsarcoma retrorectal malignant lesions, and patients with distant metastatic disease at the time of initial evaluation were excluded from analysis.
Primary resections were defined as those patients who had an attempt at curative surgery at MCR for a newly discovered retrorectal sarcoma. Secondary resections were defined as those patients who had surgery at MCR for locally recurrent tumors and also those patients who had had breach of their tumor capsule by previous subtotal resection or by an open biopsy. Patients with locally recurrent disease, previous subtotal resection, and open biopsy were considered to be high risk for local recurrence, postoperative complications, and worse survival and so were combined into 1 group for analysis purposes to see how their outcomes compared with primary resection patients. A negative surgical margin is defined as an ''R0 resection,'' a microscopically positive surgical margins is defined as an ''R1 resection.''
The type of hemipelvectomy performed depended on the extent of tumor. In patients in whom resection required loss of spinopelvic continuity, sacrifice of the lumbosacral trunk, and resection of the native hip joint, external hemipelvectomy (hindquarter amputation) was performed to obtain an R0 margin and provide viable tissue for flap closure. In patients with lesser extent of tumor, resection of a portion of the sacrum and hemipelvis (medial ilium) was possible with preservation of the limb.
Clinical records were reviewed, and data were extracted regarding demographics, clinicopathologic features, surgical technique, use of adjuvant therapy, including intraoperative radiation therapy (IORT), postoperative morbidity, and mortality. Survival free of local recurrence (LDFS), survival free of distant recurrence (DDFS), and survival free of first recurrence, either local or distant (DFS), was calculated. The histopathology was reviewed and confirmed by a pathologist.
Statistical Analysis
Descriptive statistics are reported as a percentage of the group total and continuous variables as a median and range. The Kaplan-Meier method was used to estimate OS and DFS. Associations between variables and either OS or DFS were assessed using Cox proportional hazards regression, and results reported as hazard ratio (HR) and 95% confidence interval (95% CI). The alpha level was set at .05 for statistical significance.
RESULTS
A total of 37 patients (20 males) with a median age of 49 years (range, 22-81 years) were identified. Of these, 26 patients presented with primary tumors, 11 with secondary tumors (5 with locally recurrent lesions, 6 with incompletely excised lesions or open biopsies). Table 1 outlines the histopathological features of the tumors. The median tumor size was 10 cm (range, 4.5-27 cm), and most tumors were high grade. The stage distribution for our cohort is shown in Table 2 . Stage III disease was the most common presentation, and no patients were node-positive. 
